Dividends CalendarEarnings Calendar

ALBO | Albireo Pharma

Albireo Pharma

Company profile

  • Industry: Biotechnology
  • Sector: Healthcare
  • Headquarters:   Boston, Massachusetts, United States
  • Number of employees::   90

Company profile

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo?s lead product candidate, odevixibat (A4250), is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo?s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.

  • Subsidiaries:   Elobix AB, Albireo, Inc.


10 Post Office Square
Suite 1000
Boston, MA 02109
United States

    Key Persons / Board of Directors

    • CEO :  Ron Cooper
    • General Counsel :  Jason Duncan
    • Managing Director :  Jan Mattsson
    • Chief Medical Officer :  Patrick Horn

    Videos about Albireo Pharma

    Jump to (Finance sites)

    Their Official Profiles 


    Other stocks 

    mcd pg hpq apc t orcl lrcx cyh tol ryaay insy docu 

    Support this project

    If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
    More features coming soon :)

    Social Media 

    Recommended Books

    The Internet of Money
    Buy on Amazon

    While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology.